IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
Orphan drugs — which target rare diseases affecting fewer than 200,000 people in the United States — present a number of development and manufacturing hurdles. First, because they are administered to limited patient populations, orphan drugs are produced in smaller quantities than traditional drugs, often making it difficult to place a manufacturing campaign at a reputable commercial supplier. Also, the drug substances in orphan drugs are highly complex, requiring novel and sophisticated synthetic routes and production methods. Partnering with a CDMO that offers dedicated small-scale API manufacturing services can make or break an orphan drug project, and Cambrex is equipped to excel in this area.
As a leading commercial manufacturer, Cambrex has the expertise to handle your unique manufacturing challenges, and we have added to our capacity to offer truly comprehensive small-scale manufacturing services. Our recent expansion at our High Point, NC site grew the current clinical API production footprint while also adding capacity for small-volume commercial manufacturing. The facility now has three new commercial manufacturing suites to support API manufacturing at the 2000 L scale. This allows services at High Point to more closely match Cambrex commercial sites and help to facilitate seamless scale-up while leveraging our existing commercial manufacturing expertise.
Our experts work closely with your team and are completely invested in your orphan drug’s success and helping you navigate your unique small-scale API manufacturing challenges.
We love challenges, and we would like to learn more about yours. Contact us to discuss your small-volume commercial program.